COMPUGEN, BIOSITE ANNOUNCE COLLABORATION

Compugen and Biosite announced a collaboration where Biosite is licensed to develop and commercialize immunoassay based diagnostic products using biomarkers discovered by Compugen.

In return, using its genomic platform and other computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by Biosite. Compugen will receive milestone payments and royalties from the sales of each diagnostic product emerging from the collaboration. Compugen retains the exclusive right to pursue further development in the therapeutic field, and Biosite will be entitled to receive from Compugen milestone payments and royalties arising from any successful therapeutic application.

Compugen's discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's genomic platform. The result of this analysis is utilized with a variety of discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.